Citadel Advisors - RECRO PHARMA INC ownership

RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 70 filers reported holding RECRO PHARMA INC in Q4 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.0%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of RECRO PHARMA INC
ValueSharesWeighting
Q3 2023$32,701
-65.5%
69,725
-19.2%
0.00%
Q2 2023$94,872
-3.3%
86,247
+4.6%
0.00%
Q1 2023$98,150
+124.8%
82,479
+181.5%
0.00%
Q4 2022$43,657
-80.9%
29,300
-79.1%
0.00%
Q3 2022$229,000
+59.0%
140,460
-22.7%
0.00%
Q2 2022$144,000
-66.7%
181,678
-24.3%
0.00%
Q1 2022$432,000
+14.3%
239,841
+8.4%
0.00%
Q4 2021$378,000
-39.9%
221,164
-27.6%
0.00%
Q3 2021$629,000
-2.6%
305,486
+9.1%
0.00%
Q2 2021$646,000
+26.4%
279,887
+53.0%
0.00%
Q1 2021$511,000
+396.1%
182,954
+407.7%
0.00%
Q4 2020$103,000
+58.5%
36,034
+153.8%
0.00%
Q2 2020$65,000
-90.0%
14,200
-82.2%
0.00%
Q1 2020$651,000
-64.0%
79,706
-19.1%
0.00%
-100.0%
Q4 2019$1,806,000
+1171.8%
98,538
+603.8%
0.00%
Q2 2019$142,000
-17.4%
14,000
-52.1%
0.00%
Q1 2019$172,000
+77.3%
29,258
+113.7%
0.00%
Q4 2018$97,000
-57.6%
13,692
-57.4%
0.00%
Q3 2018$229,000
+81.7%
32,149
+181.6%
0.00%
Q1 2018$126,00011,4180.00%
Other shareholders
RECRO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
MAK CAPITAL ONE LLC 850,129$2,423,0000.65%
Newtyn Management, LLC 700,000$1,995,0000.46%
Portolan Capital Management 1,293,376$3,686,0000.34%
Rubric Capital Management LP 1,076,587$3,068,0000.22%
ESSEX INVESTMENT MANAGEMENT CO LLC 99,046$282,0000.04%
Alyeska Investment Group, L.P. 736,821$2,100,0000.03%
STEPHENS INC /AR/ 510,569$1,455,0000.03%
Clear Harbor Asset Management, LLC 46,682$133,0000.02%
WYNNEFIELD CAPITAL INC 13,000$37,0000.02%
JACOBS LEVY EQUITY MANAGEMENT, INC 451,301$1,286,0000.01%
View complete list of RECRO PHARMA INC shareholders